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ABSTRACT
Introduction: Tumor necrosis factor-a (TNF-a)
is a multifunctional, proinflammatory cytokine
that mediates pleiotropic biological functions,
especially inflammation and immunoregula-
tion. We hypothesized that blocking TNF-a
with a monoclonal antibody would decrease
inflammation and subconjunctival scarring in
an animal model of experimental filtration
surgery.
Methods: In a randomized, prospective,
masked-observer study, 30 New Zealand albino
rabbits underwent glaucoma filtration surgery.
The animals were allocated to receive either
intraoperative application of infliximab (group
A) or mitomycin C (MMC) at a concentration of
0.2 mg/ml (group B) or balanced salt solution
(BSS, control) (group C). Different infliximab
doses, namely 1.0, 2.0, 3.0, 4.0, 5.0 mg in
0.1 ml, were applied. Bleb survival and charac-
teristics were evaluated over a 30-day period.
The animals were killed on postoperative day 15
or 30. Histology of the operated eyes was per-
formed to evaluate and grade the amount of
scarring in each group. Cellular density was
evaluated in each case.
Results: Infliximab did not appear to improve
outcomes in this model of glaucoma filtration
surgery. Bleb survival was significantly higher in
the MMC group compared to the other groups
(p\0.001 for both comparisons). Vascularity
was also significantly lower in the MMC group
compared to the other groups (p = 0.018 for
both comparisons). There was a significant
decrease in cellular density in the MMC group
compared to the control (p = 0.0352) and the
infliximab group (p\001).
Conclusion: Our results have shown that tra-
beculectomies in the infliximab group failed
faster and displayed more scarring, compared to
the control and MMC groups. This outcome
suggests that the infliximab doses used in this
pilot study resulted in a subconjunctival TNF-a
concentration, which acted as a stimulator to
fibroblasts.
Keywords: Infliximab; Trabeculectomy; Tumor
necrosis factor-a
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INTRODUCTION
To date, trabeculectomy remains the procedure
of choice to lower intraocular pressure and
preserve vision for a significant number of
patients suffering from glaucoma [1]. However,
it induces tissue injury that prompts the body to
initiate a precisely orchestrated sequence of
events, the process of wound healing [2, 3]. The
latter represents the main determinant of
long-term success, as excessive subconjunctival
fibrosis, driven by fibroblasts, is the principal
cause of surgical failure [4]. Tenon’s capsule
fibroblasts are activated and guided by a variety
of molecules such as interleukins, matrix met-
alloproteinases, transforming growth factor-b
(TGF-b), tumor necrosis factor-a (TNF-a) etc. [5].
The introduction of the antimetabolites 5-flu-
orouracil (5-FU) and mitomycin C (MMC) has
allowedwound-healingmodulation, which led to
improved outcome of glaucoma filtration surgery
[6–8]. However, these agents have been associated
with potentially sight-threatening complications
[9–15]. Therefore, the use of alternative antifi-
brotic agents with more specific actions and less
cytotoxicity became evident. Over the last couple
of years new antiscarring agents have been evalu-
ated, such as matrix metalloproteinase inhibitors,
alkylphosphocholines, anti-TGF-b2 antibody,
Rho-associated protein kinase inhibitors, and
anti-vascular endothelial growth factors [16–20].
TNF-a is a multifunctional cytokine that
regulates inflammation, host defense, immune
responses, apoptosis, and organ development. It
is mainly produced by macrophages, but may
also be released by T and B lymphocytes,
fibroblasts, endothelial and epithelial cells [21].
Evidence in the literature from animal and
human studies suggests that TNF-a is an
important mediator in intraocular inflamma-
tion and angiogenesis as well. In an animal
model of diabetic retinopathy, the administra-
tion of TNF-a inhibitors was found to reduce
leukocyte adhesion and inhibit blood–retinal
barrier breakdown [22]. In experimental
autoimmune uveoretinitis, systemic treatment
with anti-TNF-a serum significantly ameliorated
disease by decreasing antigen priming during
the afferent stage of inflammation [23].
There is also considerable evidence that TNF-a
plays a key role in scarring. Antibody blockage of
TNF-a, administered either during the acute
inflammatory or scarring phase of nephrotoxic
nephritis in experimental crescentic glomeru-
lonephritis, showed that inhibition of TNF-a
reduces inflammation and renal fibrosis [24].
Neutralization of endogenous TNF-a in rats with
crescentic nephritis prevented acute glomerular
inflammation and crescent formation [25].
Anti-TNF-a treatment of patients with Crohn’s
colitis was proven to decrease the levels of serum
basic fibroblast growth factor and vascular
endothelial growth factor, two cytokines known
to promote repair in human inflammation by
modulating fibroblast and subsequently down-
regulate the process of intestinal fibrogenesis [26].
Infliximab (Remicade; Roche, Manheim,
Germany) is a chimeric IgG1 monoclonal anti-
body specific for human TNF-a and is currently
approved for the treatment of various
automimmune conditions [27–30].
Regarding ocular diseases, its efficacy has
been evaluated for the treatment of uveitis
[31–33] and keratitis [34]. Few case reports have
demonstrated that in patients on systemic
infliximab for uveitis secondary to Behc¸et dis-
ease, neither ocular inflammatory attacks nor
infectious complications were encountered post
glaucoma filtration surgery [35, 36].
To our knowledge, the safety and efficacy of
infliximab as a topical antifibrotic agent after
glaucoma filtration surgery has never been
reported. In this study we describe the use of
intraoperative infliximab injections in a rabbit
model of glaucoma filtration surgery. The study
was designed to determine whether intraopera-
tive infliximab can be safe and whether it can
improve bleb survival, compared to a control
group and a group receiving intraoperative
MMC (current gold standard).
METHODS
Animals
Thirty New Zealand albino rabbits, each
weighing 2–3 kg, between 12 and 14 weeks old
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were selected for this study. The study protocol
was reviewed and approved by the ethics com-
mittee of the Greek University of Athens. All
animals were treated in accordance with the
ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research.
Slit lamp examination was performed on all
eyes before the study. Animals with corneal or
conjunctival damage before the study were
excluded.
Surgical Procedure
Infliximab (Remicade; Roche) was reconsti-
tuted with sterile saline solution. Five different
infliximab doses were tested, namely 1.0, 2.0,
3.0, 4.0, 5.0 mg in 0.1 ml, were applied. Glau-
coma filtration surgery was performed on the
right eye of each rabbit by a single surgeon
with experience in glaucoma filtration surgery.
General anesthesia was induced by adminis-
tration of ketamine hydrochloride 50 mg/kg
and xylazine hydrochloride 5 mg/kg. Partial
thickness 7–0 silk suture was passed through
the superior peripheral cornea and the eye was
infraducted. A fornix-based conjunctival flap
was fashioned in the superior quadrant with
blunt dissection of the subconjunctival space
to a distance of 15 mm behind the limbus, and
the sclera was exposed. A rectangular, partial
thickness (3 9 4 mm) scleral flap was then
prepared with a crescent knife, until the blade
was just visible in the anterior corneal stroma.
At that point each operated eye was randomly
allocated to receive intraoperative application
of either infliximab of different concentrations
(group A), or MMC (Kyowa Hakko Kogyo Co
Ltd) at a concentration of 0.2 mg/ml (group B)
or physiological saline (Balanced Salt Solution;
Alcon Laboratories) (group C). Five sponges
measuring 3 9 1 mm were cut and soaked in
one of the three agents and subsequently
placed between the conjunctiva and the sclera,
over the determined filtration area. After 3 min
sponges were removed and the area was irri-
gated with 15 ml of physiological saline. Then
a 500-lm sclerostomy with peripheral iridec-
tomy was performed. The scleral flap was
loosely sutured with two 10–0 nylon sutures.
The conjunctiva was closed with one single
running 8–0 Vicryl suture. Intracameral
cefuroxime 1 mg/0.1 ml and subconjunctival
dexamethasone 3.3 mg/ml were administered
at the end of the procedure. Dexamethasone
and tobramycin eye drops (Tobradex; Tobra-
dex, Alcon) were used topically after the sur-
gical procedure four times daily for a week.
Clinical Assessment
Slit lamp examination was used to evaluate the
anterior chamber depth and inflammation,
changes in cornea, conjunctival appearance,
and drainage area. Assessment of both eyes
(contralateral untreated eye used as control) was
made on the first postoperative day and there-
after once weekly, until death, with a technique
previously described by Mead et al. [18]. Bleb
characteristics were assessed. The drainage bleb
vascularity characteristics were graded regard-
ing the conjunctival area surrounding the bleb
and scoring the appearance (0, avascular; ?1,
normal vascularity; ?2, hyperemic; and ?3,
very hyperemic). Slit lamp examination was
performed to identify both anterior chamber
activity (0, quiet; 1, cells; 2, fibrin; and 3,
hypopyon) and anterior chamber depth, which
was recorded as deep (?2), shallow (?1), or flat
(0). Assessment of corneal epitheliopathy was
made after topical instillation of lignocaine
fluorescein into the right eye and was graded
according to the area of the cornea affected (0,
nil; 1,\25%; 2,\50%; 3,\75%; 4,\100%; 5,
100%).
As a result of the limited provision of
non-contact tonometers, IOP measurements
were not included in the study. However, the
rabbit model of filtration surgery represents a
model of subconjunctival scarring and not of
glaucoma and therefore significant IOP differ-
ences between groups were unlikely to be
detected [18].
Histology Analysis
On days 15 or 30, animals were killed with a
lethal intravenous injection of phenobarbital
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(120 mg/kg), and the tissues were processed for
histology. The surgical eye was enucleated. The
upper lid was left intact, attached to the globe,
to preserve the architecture of the superior for-
nix and conjunctival tissues around the drai-
nage site. All the eyes were fixed in 4%
formaldehyde and embedded in paraffin wax.
Sequential 5-lm sections of the operative
wound site were prepared. The following his-
tological staining was performed: hematoxylin
and eosin (for total cellularity, inflammation),
Masson trichrome (for scar formation, collagen
density, and orientation), and oxidation alde-
hyde fuchsin (elastic fibers). Cellular density in
the bleb was regarded as a good parameter to
evaluate the bleb’s function as it depends upon
inflammation, fibrosis, and edema of the bleb.
The mean cellular density was evaluated in each
case in five high power fields (9400, 0.18 mm2).
The fibrosis and inflammation were graded as
absent, mild (\10%), moderate (\40%), and
severe ([40%).
Statistical Analysis
Statistical analysis was performed to determine
the differences between the three treatment
groups. Qualitative variables were expressed as
absolute and relative frequencies. For the com-
parison of proportions Fisher’s exact tests were
used. Random effects logistic regression analy-
ses with dependent variables bleb thickness,
vascularity, and height were used to evaluate
their changes among the different groups over
the follow-up. Odds ratio (OR) with standard
errors (SE) were computed from the results of
these models. To investigate if changes during
follow-up were different between the study
groups, the interaction term of time and group
was tested in the models. Kaplan–Meier survival
estimates for bleb failure were graphed over the
follow-up period, for each study group. Log-
rank tests were used to compare survival curves
between the three groups. All reported p values
are two-tailed. Statistical significance was set at
p\0.05 and analyses were conducted using
STATA statistical software (version 11.0).
RESULTS
Histopathology Features
Bleb Analysis
In all groups there was variability in bleb char-
acteristics, including well-formed ones, edema-
tous without significant inflammation, to very
small blebs with significant fibrosis. The MMC
group had more edematous and formed blebs
compared to the other groups. The infliximab
group had overall smaller blebs with significant
fibrosis. The inflammation was overall mild and
limited to some lymphocytes and occasional
plasmocytes more frequently located at the
limbus or the superficial stroma. In some cases a
limited foreign-body-type reaction could be
identified around suture material (Fig. 1).
Statistical Analysis
The mean cellular density in the bleb of the
infliximab group at 15 days was 50.7 cells/HPF
(9400) ± 4.9 (SEM) and 36.2 cells/HPF ± 7
(SEM) in the MMC group. The mean cellular
density in the control group at 15 days was
52.6 cells/HPF (9400) ± 3.6 (SEM). The mean
cellular density in the bleb of the infliximab
group at 30 days was 51.3 cells/HPF
(9400) ± 5.8 (SEM) and 42.25 cells/HPF ± 3.6
(SEM) in the MMC group. There was a signifi-
cant decrease in cellular density in the MMC
group compared to the control group
(p = 0.0186; Student’s t test) and the infliximab
group (p\0.01). There was no significant
decrease in cellular density in the infliximab
group compared to the control group. There
were no statistical significant differences in
cellular density between the blebs treated with
various concentrations of infliximab.
Clinical Features
In keeping with previous studies [19], anterior
chamber (AC) depth was shallow on the first
postoperative day and was deep in all rabbits by
day 7. AC remained deep in all eyes, regardless
of the treatment group throughout the study.
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During the course of the study, local tissue
reaction to treatment was assessed by bleb and
conjunctival vascularity as well as bleb
thickness.
No cases of epithelial defects or endoph-
thalmitis were recorded in either treatment
group.
Failure of surgery was defined by the
appearance of a flat, vascularized or scarred bleb
associated with a deep anterior chamber. At day
28, 8 (80%) of the control group and 10 (100%)
of the infliximab group had failed compared to
1 (11.1%) in the MMC group. The bleb failed at
a mean of 9.8 days (SE = 1.1) with infiximab,
26.4 days (SE = 1.5) with MMC, and 16.8 days
(SE = 1.9) for the controls (Table 1). A signifi-
cant difference in bleb survival was observed
between groups (log rank; p\0.001) (Fig. 2).
More specifically, greater survival was found in
the MMC group compared to the infliximab
and control groups (p\0.001 for both
comparisons), while lower survival was found in
the infliximab group compared to controls
(p = 0.003). During the follow-up, all cases
failed in the control and infliximab groups,
while only one case failed in the MMC group.
Postoperative measurements of bleb thick-
ness, for each group, are presented in Table 2.
Fig. 1 Histologic characteristics of postoperative blebs at
day 15. The images show representative sections from eyes
in each group. a, b Masson trichrome stain of the bleb of
an eye in the control group. a [Original magniﬁcation
924; b original magniﬁcation 963, cellular density 43
cells/HPF (9400, 0.18 mm2)]. c Masson trichrome stain
of the bleb of an eye in the MMC group (original
magniﬁcation 963, cellular density 23 cells/HPF).
d Hemotoxylin–eosin stain of the bleb of an eye in the
control group (original magniﬁcation 963, cellular density
39 cells/HPF). e, f Hemotoxylin–eosin stain of the bleb of
an eye in the 4-mg inﬂiximab group (e anterior part of the
bleb; f posterior part of the bleb; original magniﬁcation
963, cellular density 49 cells/HPF)
Table 1 Time at which the blebs failed after surgery in
each treatment group
Group Days after surgery
1 7 14 21 28
Control 0 0 8 0 2
Inﬂiximab 0 6 4 0 0
MMC 0 0 1 0 0
The mean day of failure was 9.8 for inﬂiximab, 26.4 for
MMC, and 16.8 for the controls, n = 10 in all groups
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There were no significant differences between
the study groups at each time point (p[0.050).
Postoperativemeasurements of bleb vascularity
for each group are presented in Table 3. At the first
and seventh postoperative day, the percentage of
moderate/severe vascularity was significantly
higher in the control group compared to theMMC
group. Also, the percentages of moderate/severe
vascularity decreased significantly during fol-
low-up measurements in the infliximab group
(b=-0.02; SE= 0.01; p= 0.014) and in the con-
trol group (b=-0.04; SE= 0.01; p\0.001), while
in theMMCgroup therewas no significant change
(b= 0.002; SE= 0.01; p= 0.662) as indicated from
the interaction term of the model (Fig. 3).
Postoperative measurements of bleb height,
for each group, are presented in Table 4. All
rabbits had a bleb height of 1 or 2 at the first
postoperative day, regardless of the group. At
day 7 and day 21 postsurgery, the percentages of
bleb height 1 or 2 were significantly higher in
the MMC group compared to infliximab group.
Moreover, at day 14 and day 28 the percentages
of bleb height 1 or 2 were significantly higher in
the MMC group compared to both the inflix-
imab and control groups.
Random effects logistic regression analyses,
for bleb thickness, showed a significant increase
in the likelihood for having thick bleb during
the follow-up (ORtime = 1.09, 96% CI 1.02–1.17,
p = 0.014). Also, a significant interaction effect
of time with group was found (p = 0.031; Fig. 4)
indicating that in the infliximab and MMC
groups there was an increase in the probability
of having thick bleb, whilst no changes were
observed in the control group.
Random effects analyses for vascularity
showed a significant decrease in the odds of
having moderate or severe vascularity during
follow-up (ORtime = 0.86, 96% CI 0.65–0.89,
p = 0.001). Lower odds for the presence of
moderate or severe vascularity were found in
the infliximab group as compared to controls
(OR = 0.06, 96% CI 0.01–0.49, p = 0.009) and in
the MMC group as compared to controls
(OR = 0.01, 96% CI 0.001–0.13, p = 0.002).
Fig. 2 Kaplan–Meier estimates showing bleb survival curves for the study groups
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The interaction term of time with group as
presented in Fig. 3 was significant (p = 0.018)
showing that in the MMC group the likelihood
for the presence of moderate or severe vascu-
larity was lower and constant, while in the two
others groups a decrease was recorded.
With regards to bleb height analysis, a sig-
nificant decrease in the likelihood for the pres-
ence of heights 1–2 (ORtime = 0.32, 96% CI
0.11–0.97, p = 0.045) was shown. The MMC
group had greater odds for the presence of
heights 1–2, while the no interaction effect was
found indicating that the three groups had
similar changes during the follow-up (Fig. 5).
DISCUSSION
Glaucoma filtration surgery induces tissue injury
that stimulates the body to commence the pro-
cess of wound healing [37]. TNF-a plays a vital
role throughout this process, as it participates in
clotting, inflammation, and apoptosis [21, 38].
We hypothesized that blocking TNF-a with
infliximab would reduce both inflammation and
fibrosis post glaucoma filtration surgery and
consequently enhance bleb survival.
Multiple studies in animal models and
humans have demonstrated the beneficial effect
of TNF-a blockage in the treatment of systemic
and ophthalmic inflammatory diseases
[22, 23, 27–30]. However, the in vivo and
in vitro data on the role of infliximab in
angiogenesis and wound healing have been
controversial.
Angiogenesis is indispensable in the forma-
tion of granulation tissue during the prolifera-
tive phase of wound healing. TNF-a can trigger
opposite signaling pathways involved in
angiogenesis, evoking apoptosis or cell survival
and proliferation, depending on the tissues and
underlying pathology [39–41]. Regatieri et al.
examined the effects of infliximab in angio-
genesis modulation and glycosaminoglycan
expression in choroidal neovascularization
lesions and concluded that it demonstrates a
dual effect depending on the concentration and
it may reduce angiogenesis and glycosamino-
glycan expression at low doses, whereas oppo-
site effects are observed at high doses [42].
Table 2 Postoperative measurements of bleb thickness for each group
Thickness
Day 1 Day 7 Day 14 Day 21 Day 28
Thin Thick Thin Thick Thin Thick Thin Thick Thin Thick
Group N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Control 7 (70.0) 3 (30.0) 10
(100.0)
0 (0.0) 9 (90.0) 1 (10.0) 5 (100.0) 0 (0.0) 4 (80.0) 1 (20.0)
Inﬂiximab 10
(100.0)
0 (0.0) 7 (70.0) 3 (30.0) 6 (60.0) 4 (40.0) 3 (60.0) 2 (40.0) 2 (40.0) 3 (60.0)
MMC 9 (100.0) 0 (0.0) 8 (88.9) 1 (11.1) 7 (77.8) 2 (22.2) 2 (50.0) 2 (50.0) 2 (50.0) 2 (50.0)
p* control vs
inﬂiximab
0.211 0.211 0.303 0.444 0.524
p* control vs
MMC
0.211 0.474 0.582 0.167 0.524
p* inﬂiximab
vs MMC
–? 0.582 0.628 1.000 1.000
* Fisher’s exact test
? Not computed as a result of no distribution
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With regards to wound healing and fibrosis,
the results of studies are equally equivocal
[43, 44]. Multiple studies assessing the systemic
effect of anti-TNF in renal and colorectal fibrosis
reported a favorable result of the antibody on
tubulointerstitial scarring and interstitial fibro-
genesis [24–26]. Mooney et al. reported that
local application of TNF-a accelerated wound
healing in murines [45]. In contrast Rapala et al.
[43] and Salomon et al. [44] concluded that
TNF-a impaired wound healing. These opposing
effects of TNF-a could be attributed to its effect
on the production of collagen and collagenase.
Austgulen et al. suggested that TNF-a affects the
accumulation of extracellular matrix molecules
by promoting or inhibiting the activity of col-
lagenases [46]. Other studies though indicate
that TNF-a may play a predominantly catabolic
role in situ by inhibiting fibronectin produc-
tion, indirectly increasing dermal fibroblast
elaboration of collagenase and proteoglycan
activities, thus causing the degradation of col-
lagen and glycosaminoglycan [47].
The opposing actions of TNF-a could be
explained as follows. TNF is a pluripotent,
proinflammatory cytokine that mediates pleio-
tropic biological functions as a direct conse-
quence of its ability to induce the expression of
a large number of gene products. With regards
to its inflammatory properties, binding to
TNFR2 may either induce activation of the
NF-jB pathway with subsequent expression of
several anti-apoptotic genes or conversely
stimulate apoptosis by inhibiting the NF-jB
pathway. The model proposed to explain the
contradictory functions of TNF suggests that
apoptosis is induced when the complex of
TNF-a/TNFR1 is internalized within endocytic
vesicles with subsequent altered signaling
pathways. However it is unclear which factors
define the cascade of events post formation of
the TNF-a/TNFR1 complex [21]. TNF-a concen-
tration my play a role. Reports have demon-
strated that at low concentrations TNF-a may
act on fibroblasts as a growth inducer, by stim-
ulating proliferation. In contrast, at higher
concentrations, it can act as a growth inhibitor,
by blocking growth triggered by serum and
other cytokines [48].
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Our results have shown that trabeculec-
tomies in the infliximab group failed faster and
displayed more scarring, compared to the con-
trol and MMC groups. Vascularity though was
less significant in the infliximab group com-
pared to the control group. This outcome sug-
gests that the infliximab doses used in this pilot
study resulted in a subconjunctival TNF-a
concentration, which probably acted as a stim-
ulator to fibroblasts, but not for angiogenesis.
In order to reproduce the current golden
standard technique of MMC application,
infliximab was administered under the con-
junctiva through soaked sponges, in a prede-
termined filtration area, and then irrigated with
saline. It is unknown whether the same con-
centrations of infliximab would have produced
different clinical outcomes had it not been
washed out or had it been administered
through a subconjunctival injection at the
beginning of surgery.
Our data also showed a statistically signifi-
cant decrease in cellular density in the MMC
group, compared to the other groups. This
echoes multiple studies demonstrating that
MMC causes widespread cell death and apop-
tosis [12].
No differences were found in cellular density
and scarring amongst various concentrations of
infliximab. This could imply that for topical
infliximab administration, larger concentration
variances would be required to produce a
detectable clinical difference.
Fig. 3 Linear predictors for moderate/severe bleb vascu-
larity through follow-up period, for each study group
Table 4 Post-op measurements of bleb height for each group
Height
Day 1 Day 7 Day 14 Day 21 Day 28
0 1–2 0 1–2 0 1–2 0 1–2 0 1–2
Group N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Control 0 (0) 10 (100.0) 2 (20.0) 8 (80.0) 7 (70.0) 3 (30.0) 3 (60.0) 2 (40.0) 5 (100.0) 0 (0)
Inﬂiximab 0 (0) 10 (100.0) 6 (60.0) 4 (40.0) 10 (100.0) 0 (0.0) 5 (100.0) 0 (0) 5 (100.0) 0 (0)
MMC 0 (0) 9 (100.0) 0 (0.0) 9 (100.0) 1 (11.1) 8 (88.9) 1 (25.0) 3 (75.0) 1 (25.0) 3 (75.0)
p* control vs
inﬂiximab
–? 0.170 0.211 0.444 –?
p* control vs
MMC
–? 0.474 0.020 0.524 0.048
p* inﬂiximab
vs MMC
–? 0.011 \0.001 0.048 0.048
* Fisher’s exact test
? Was not computed due to no distribution
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Our study is preliminary and is limited by
the following considerations. The number of
rabbits used in this study was not sufficient to
draw final conclusions regarding intraoperative
safety and efficacy of infliximab. Cell culture
experiments, which would demonstrate the
optimum infliximab concentration with no
cellular toxicity, while demonstrating maxi-
mum inhibition of angiogenesis and fibrosis,
were not performed. Also, as a result of limita-
tions in human resources, a 7-day interval time
in-between observations under anesthesia was
chosen, resulting in possible overestimation of
the exact timing of bleb failure. These are
important caveats when extrapolating our
studies to safety and efficacy in human subjects.
Further studies will be required to determine the
effective dose of intraoperative infliximab.
CONCLUSION
Our outcomes indicate that infliximab, when
administered subconjunctivally during experi-
mental glaucoma filtration surgery in concen-
trations ranging from 10 to 50 mg/ml,
accelerates scarring and bleb failure. The ideal
antifibrotic agent, which will modulate wound
healing whilst minimizing side effects, is yet to
be defined.
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